Dr. Blagosklonny received M.D. (internal medicine) and Ph.D. (experimental medicine, cardiology) from IP Pavlov Leningrad Medical University (St-Petersburg, Russia) and then conducted pre-clinical and clinical investigations in hematology, oncology and cardiology. In 1991, he moved to the Clinical Pharmacology Branch of the National Cancer Institute, National Institutes of Health (Bethesda, MD), where he conducted both basic research and clinical trials.

In 2002, he was appointed Associate Professor of Medicine at New York Medical College, Valhalla, NY and then was recruited as Senior Scientist at Ordway Research Institute, Albany, NY. In 2009, he was appointed Professor/Member at Roswell Park Cancer Institute. His research interests range from molecular and cellular biology to clinical investigations and specifically include oncogenes and tumor suppressors, signal transduction, cell cycle, mitosis, apoptosis, anticancer therapeutics with emphasis on translation of basic science into new anticancer strategies such as exploiting cancer cell cycling and drug resistance for selective protection of normal cells. He has extended this approach to other age-related diseases and aging itself, thus revealing an anti-aging drug to be used today (Cell Cycle, 2006, 5 : 2087 - 2102).

Dr. Blagosklonny is the author of over 170 research articles, reviews and book chapters. He is the Founding Editor and Editor-in-Chief of Cell Cycle and also Co-editor and co-founder of Aging and also serves as an Associate Editor for Cancer Biology & Therapy, Autophagy, Cancer Research, Cell Death and Differentiation, International Journal of Cancer, The American Journal of Pathology and PLOS ONE.